期刊
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
卷 11, 期 1, 页码 670-678出版社
WILEY
DOI: 10.1016/j.dadm.2019.08.004
关键词
Subjective cognitive decline; Amyloid; APOE epsilon 4; Alzheimer's disease
资金
- NHMRC Dementia Research Fellowship [APP1105576]
- Canadian Institutes of Health Research Postdoctoral Fellowship
- National Institutes of Health [P01 AG036694, P50 AG005134, K23 EB019023, K23 AG049087, K24 AG035007, K01 040197]
- Center for Functional Neuroimaging Technologies [P41EB015896]
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institutes of Health
- NIH [S10RR021110, S10RR023401, S10RR023043]
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
- DODADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- BioClinica, Inc.
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Cogstate
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Lumosity
- Lundbeck
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC.
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
- Canadian Institutes of Health Research
Introduction: We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of beta-amyloid (A beta) positron emission tomography scans required for recruiting A beta+ clinically normal individuals in clinical trials. Methods: Three independent cohorts (890 clinically normal: 72 yrs 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [APOE] epsilon 4+: 28.5%; A beta+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified A beta+ using the SCD dichotomy, APOE epsilon 4, sex, and age. Results: SCD increased odds of A beta+ by 1.58 relative to non-SCD. Female APOE epsilon 4 carriers with SCD exhibited higher odds of A beta+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of A beta positron emission tomography scans to recruit A beta+ individuals by 13% and by 9% if APOE epsilon 4 status is known. Conclusion: SCD helps to classify those with high A beta, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据